Clinical Significance

CA19-9 is a tumor marker associated with pancreatic cancer, gallbladder cancer, colon cancer and gastric cancer, also known as gastrointestinal tract-associated antigen. CA19-9 and CA242, CA50 have close epitopes, but because of the difference in specificity of monoclonal antibodies, they have different clinical values for diagnosis and monitoring. CA19-9 has high sensitivity and good specificity for pancreatic cancer, and its positive rate is between 85% and 95%, and it decreases with the improvement of the condition after surgery.